Abbott Laboratories
ABT · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -4.54 | 0.96 | -0.51 | 0.01 |
| FCF Yield | 0.98% | 0.65% | 0.40% | 1.10% |
| EV / EBITDA | 107.77 | 79.79 | 89.38 | 68.09 |
| Quality | ||||
| ROIC | 2.16% | 2.39% | 1.82% | 13.11% |
| Gross Margin | 55.75% | 56.44% | 52.56% | 51.01% |
| Cash Conversion Ratio | 1.70 | 1.15 | 1.07 | 0.31 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.14% | 2.33% | 0.67% | -1.32% |
| Free Cash Flow Growth | 48.28% | 65.59% | -56.56% | -0.05% |
| Safety | ||||
| Net Debt / EBITDA | 2.44 | 2.13 | 2.51 | 2.56 |
| Interest Coverage | 46.14 | 16.96 | 12.60 | 13.09 |
| Efficiency | ||||
| Inventory Turnover | 0.75 | 0.70 | 0.74 | 0.87 |
| Cash Conversion Cycle | 128.56 | 131.75 | 108.08 | 90.26 |